

Supporting Information

**Synthesis of *N*-Acylbenzimidazoles through [4 + 1] Annulation of *N*-Arylpivalimidamides
with Dioxazolones**

Xia Song[†], Xinyuan Cai[‡], Xinying Zhang^{‡,*}, Xuesen Fan^{‡,*}

[†]*School of Environment, Key Laboratory for Yellow River and Huai River Water Environmental Pollution*

Control, Ministry of Education, Henan Normal University, Xinxiang, Henan 453007, China

[‡]*NMPA Key Laboratory for Research and Evaluation of Innovative Drug, Collaborative Innovation Center of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 453007, China*

E-mail: xinyingzhang@htu.cn; xuesen.fan@htu.cn

Table of Contents

I	General experimental information	S3
II	Experimental procedures and spectroscopic data	S4-S18
III	Mechanism studies	S19-S24
IV	Copies of NMR spectra of products 3a-3mm	S25-S66
V	Copies of NMR spectra of products 4-7	S67-S70
VI	Copies of NMR spectra of intermediate IV	S71
VII	X-ray crystal structure and data of product 3o	S72-S73
VIII	References	S74

I. General experimental information

Commercial reagents were used without further purification. Amidines (**1**),^[1] dioxazolones (**2**),^[2] and $[\text{RhCp}^*\text{Cl}_2]_2$ ^[3] were prepared based on literature procedures. Melting points were recorded with a micro melting point apparatus and uncorrected. The ^1H NMR spectra were recorded at 400 MHz or 600 MHz. The ^{13}C NMR spectra were recorded at 100 MHz or 150 MHz. The ^{19}F NMR spectra were recorded at 565 MHz. Chemical shifts were expressed in parts per million (δ), and were reported as s (singlet), d (doublet), t (triplet), dd (doublet of doublet), m (multiplet), br s (broad singlet), etc. The coupling constants J were given in Hz. High resolution mass spectra (HRMS) were obtained *via* ESI mode by using a MicrOTOF mass spectrometer. All reactions were monitored by thin layer chromatography (TLC) using silica gel plates (silica gel 60 F254 0.25 mm), and components were visualized by observation under UV light (254 and 365 nm).

II. Experimental procedures and spectroscopic data

1. Typical procedures for the synthesis of **3a** and spectroscopic data of **3a-3mm**

To a reaction tube equipped with a stir bar were charged with *N*-phenylpivalimidamide (**1a**, 63.5 mg, 0.36 mmol), ethyl acetate (1.5 mL), [RhCp^{*}Cl₂]₂ (4.6 mg, 0.0075 mmol), AgSbF₆ (10.3 mg, 0.03 mmol), Zn(OAc)₂ (16.5 mg, 0.09 mmol) and 3-phenyl-1,4,2-dioxazol-5-one (**2a**, 48.9 mg, 0.3 mmol). The tube was then sealed, and the resulting mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (69.3 mg, 83%). **3b-3mm** were obtained in a similar manner.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (**3a**)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (69.3 mg, 83%), mp 142-144 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.82 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 2H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.73-7.69 (m, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.24-7.20 (m, 1H), 7.05-7.01 (m, 1H), 6.56 (d, *J* = 8.4 Hz, 1H), 1.57 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.8, 163.3, 141.4, 135.4, 134.9, 133.0, 130.9, 129.3, 123.3, 123.1, 119.7, 112.2, 35.4, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₉N₂O 279.1492; Found 279.1509.

(2-(*tert*-Butyl)-6-methyl-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (**3b**)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (67.5 mg, 77%), mp 130-132 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.82 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 2H), 7.72-7.69 (m, 1H), 7.63 (d, *J* = 7.8 Hz, 1H), 7.53-7.51 (m, 2H), 7.04 (dd, *J*₁ = 8.4 Hz, *J*₂ = 1.2 Hz, 1H), 6.35 (s, 1H), 2.24 (s, 3H), 1.55 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.9, 162.6, 139.5, 135.7, 134.9, 133.3, 133.0, 130.9, 129.3, 124.5, 119.2, 112.1, 35.4, 29.8, 21.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₂₁N₂O 293.1648; Found 293.1649.

(2-(*tert*-Butyl)-6-methoxy-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3c)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (68.5 mg, 74%), mp 99-101 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.82 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 2H), 7.72-7.69 (m, 1H), 7.64 (d, $J = 9.0$ Hz, 1H), 7.54-7.51 (m, 2H), 6.84 (dd, $J_1 = 9.0$ Hz, $J_2 = 2.4$ Hz, 1H), 6.03 (d, $J = 2.4$ Hz, 1H), 3.56 (s, 3H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.8, 162.3, 156.5, 136.0, 134.9, 132.9, 130.9, 129.3, 120.0, 111.3, 97.0, 55.6, 35.4, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ 309.1598; Found 309.1599.

(2-(*tert*-Butyl)-6-isopropyl-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3d)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (84.1 mg, 88%), mp 101-103 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.83 (d, $J_1 = 8.4$ Hz, $J_2 = 1.2$, 2H), 7.71-7.68 (m, 1H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.52 (t, $J = 8.4$ Hz, 2H), 7.10 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$, 1H), 6.35 (d, $J = 1.2$ Hz, 1H), 2.79-2.75 (m, 1H), 1.56 (s, 9H), 1.05 (d, $J = 6.6$ Hz, 6H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.9, 162.9, 144.5, 139.8, 135.6, 134.8, 133.2, 130.9, 129.2, 122.1, 119.3, 109.8, 35.4, 34.2, 29.8, 24.2. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}$ 321.1961; Found 321.1967.

(2-(*tert*-Butyl)-6-fluoro-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3e)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (55.1 mg, 62%), mp 129-131 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.81 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 2H), 7.75-7.72 (m, 1H), 7.69-7.67 (m, 1H), 7.56-7.53 (m, 2H), 6.98-6.95 (m, 1H), 6.25 (dd, $J_1 = 9.0$ Hz, $J_2 = 2.4$ Hz, 1H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.3, 163.8 (d, $^4J_{\text{C-F}} = 3.6$ Hz), 159.5 (d, $^1J_{\text{C-F}} = 239.8$ Hz), 137.8, 135.4 (d, $^3J_{\text{C-F}} = 13.0$ Hz), 135.2, 132.4, 130.9, 129.5, 120.4 (d, $^3J_{\text{C-F}} = 9.4$ Hz), 111.3 (d, $^2J_{\text{C-F}} = 24.5$ Hz), 99.3 (d, $^2J_{\text{C-F}} = 28.1$ Hz), 35.5, 29.7. ^{19}F NMR (CDCl_3 , 565 MHz): δ -117.60--117.64 (m). HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{18}\text{FN}_2\text{O}$ 297.1398; Found 297.1401.

(2-(*tert*-Butyl)-6-chloro-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3f)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (71.3 mg, 76%), mp 136-138 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.82-7.80 (m, 2H), 7.75-7.72 (m, 1H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.56-7.53 (m, 2H), 7.20 (dd, $J_1 = 9.0$ Hz, $J_2 = 2.4$ Hz, 1H), 6.57 (d, $J = 1.8$ Hz, 1H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.2, 164.0, 140.1, 135.9, 135.4, 132.3, 130.9, 129.5, 128.9, 123.8, 120.5, 112.1, 35.5, 29.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}$ 313.1102; Found 313.1104.

(6-Bromo-2-(*tert*-butyl)-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3g)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (75.0 mg, 70%), mp 163-165 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.82-7.80 (m, 2H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.62 (d, $J = 8.4$ Hz, 1H), 7.55 (t, $J = 8.0$ Hz, 2H), 7.34 (dd, $J_1 = 8.8$ Hz, $J_2 = 2.0$ Hz, 1H), 6.73 (d, $J = 1.6$ Hz, 1H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.2, 163.8, 140.5, 136.4, 135.4, 132.3, 131.0, 129.5, 126.5, 121.0, 116.4, 114.9, 35.5, 29.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{BrN}_2\text{O}$ 357.0597; Found 357.0585.

(2-(*tert*-Butyl)-6-iodo-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3h)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (75.2 mg, 62%), mp 179-180 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.80 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 2H), 7.76-7.73 (m, 1H), 7.57-7.52 (m, 4H), 6.92 (s, 1H), 1.54 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.2, 163.6, 141.0, 136.8, 135.4, 132.3, 132.2, 131.0, 129.5, 121.4, 120.8, 86.7, 35.4, 29.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{IN}_2\text{O}$ 405.0458; Found 405.0454.

(2-(*tert*-Butyl)-6-nitro-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3i)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (42 mg, 43%), mp 158-160 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 8.18 (dd, $J_1 = 9.0$ Hz, $J_2 = 2.4$ Hz, 1H), 7.84-7.82 (m, 3H), 7.79 (t, $J = 7.8$ Hz, 1H), 7.60-7.56 (m, 3H), 1.57 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.6, 168.1, 145.9, 143.8, 136.0, 134.8, 131.8, 131.1, 129.8, 119.8, 119.0, 108.4, 35.9, 29.6. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_3$ 324.1343; Found 324.1334.

(2-(*tert*-Butyl)-6-phenyl-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3j)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (65.9 mg, 62%), mp 213-216 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.87-7.85 (m, 2H), 7.81 (d, J = 8.4 Hz, 1H), 7.72 (t, J = 7.8 Hz, 1H), 7.53 (t, J = 8.4 Hz, 2H), 7.46 (dd, J_1 = 8.4 Hz, J_2 = 1.8 Hz, 1H), 7.34-7.30 (m, 4H), 7.27-7.24 (m, 1H), 6.74 (d, J = 1.2 Hz, 1H), 1.58 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.7, 163.7, 141.4, 140.9, 137.0, 136.0, 135.1, 132.9, 131.0, 129.4, 128.7, 127.3, 127.0, 123.0, 119.8, 110.7, 35.5, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}$ 355.1805; Found 355.1797.

(2-(*tert*-Butyl)-5-methyl-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3k)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (70.2 mg, 80%), mp 147-149 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.82-7.80 (m, 2H), 7.69 (t, J = 7.6 Hz, 1H), 7.55 (s, 1H), 7.55-7.49 (m, 2H), 6.84 (dd, J_1 = 8.4 Hz, J_2 = 0.8 Hz, 1H), 6.41 (d, J = 8.4 Hz, 1H), 2.40 (s, 3H), 1.57 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.7, 163.3, 141.7, 134.8, 133.5, 133.1, 132.8, 130.9, 129.2, 124.5, 119.6, 111.8, 35.4, 29.7, 21.4. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ 293.1648; Found 293.1635.

(2-(*tert*-Butyl)-5-chloro-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3l)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (74.1 mg, 79%), mp 167-169 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.80 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 2H), 7.74-7.73 (m, 1H), 7.72-7.71 (m, 1H), 7.54-7.52 (m, 2H), 6.99 (dd, J_1 = 9.0 Hz, J_2 = 2.4 Hz, 1H), 6.47 (d, J = 8.4 Hz, 1H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.2, 164.6, 142.4, 135.2, 134.0, 132.6, 130.9, 129.4, 128.7, 123.6, 119.6, 112.8, 35.5, 29.6. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}$ 313.1102; Found 313.1101.

(2-(*tert*-Butyl)-4-methyl-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3m)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (75.4 mg, 86%), mp 135-136 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.86 (d, J = 7.6 Hz, 2H), 7.73 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 8.0 Hz, 2H), 7.06 (d, J = 7.6 Hz,

1H), 6.95 (t, J = 8.0 Hz, 1H), 6.41 (d, J = 8.4 Hz, 1H), 2.72 (s, 3H), 1.62 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 171.0, 162.2, 140.8, 135.2, 134.7, 133.2, 130.9, 129.9, 129.2, 123.4, 123.0, 109.6, 35.5, 29.8, 16.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ 293.1648; Found 293.1648.

(2-(*tert*-Butyl)-4-chloro-1*H*-benzo[*d*]imidazol-1-yl)(phenyl)methanone (3n)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (81.6 mg, 87%), mp 143-145 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.80-7.78 (m, 2H), 7.73-7.70 (m, 1H), 7.53-7.51 (m, 2H), 7.23 (dd, J_1 = 7.8 Hz, J_2 = 0.6 Hz, 1H), 6.95 (t, J = 8.4 Hz, 1H), 6.49 (dd, J_1 = 8.4 Hz, J_2 = 1.2 Hz, 1H), 1.57 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.3, 163.7, 138.9, 136.4, 135.2, 132.5, 131.0, 129.4, 124.7, 123.7, 123.0, 110.6, 35.6, 29.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}$ 313.1102; Found 313.1106.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(*p*-tolyl)methanone (3o)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (64.9 mg, 74%), mp 120-122 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.76 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.31 (d, J = 7.8 Hz, 2H), 7.22 (t, J = 7.8 Hz, 1H), 7.05-7.02 (m, 1H), 6.62 (d, J = 8.4 Hz, 1H), 2.47 (s, 3H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.6, 163.1, 146.4, 141.4, 135.5, 131.1, 130.2, 130.0, 123.2, 123.0, 119.7, 112.1, 35.4, 29.8, 21.9. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ 293.1648; Found 293.1643.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-methoxyphenyl)methanone (3p)^[4]

Eluent: petroleum ether/ethyl acetate (10:1). White solid (75.9 mg, 82%), mp 151-153 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.80-7.78 (m, 2H), 7.77 (d, J = 8.4 Hz, 1H), 7.23-7.20 (m, 1H), 7.07-7.04 (m, 1H), 6.98-6.95 (m, 2H), 6.69 (d, J = 7.8 Hz, 1H), 3.90 (s, 3H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.9, 165.2, 163.0, 141.3, 135.7, 133.6, 125.0, 123.1, 122.9, 119.6, 114.6, 111.9, 55.7, 35.3, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}_2$ 309.1598; Found 309.1590.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-(*tert*-butyl)phenyl)methanone (3q)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (56.2 mg, 56%), mp 165-167 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.78-7.74 (m, 3H), 7.52-7.50 (m, 2H), 7.23-7.21 (m, 1H), 7.06-7.03 (m, 1H), 6.64 (d, J = 7.8 Hz, 1H), 1.56 (s, 9H), 1.37 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 170.6, 163.1, 159.3, 141.4, 135.6, 131.0, 130.0, 126.3, 123.2, 122.9, 119.6, 112.1, 35.5, 35.4, 31.0, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{22}\text{H}_{27}\text{N}_2\text{O}$ 335.2118; Found 335.2118.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-fluorophenyl)methanone (3r)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (68.0 mg, 76%), mp 124-126 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.88-7.84 (m, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.25-7.17 (m, 3H), 7.08-7.03 (m, 1H), 6.59 (d, J = 8.0 Hz, 1H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 169.5, 166.8 (d, $^1J_{\text{C}-\text{F}} = 257.1$ Hz), 163.1, 141.5, 135.3, 133.8 (d, $^3J_{\text{C}-\text{F}} = 9.3$ Hz), 129.2 (d, $^4J_{\text{C}-\text{F}} = 2.8$ Hz), 123.4, 123.2, 119.9, 116.7 (d, $^2J_{\text{C}-\text{F}} = 22.4$ Hz), 111.9, 35.4, 29.7. ^{19}F NMR (CDCl_3 , 565 MHz): δ -101.0--101.1 (m). HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{18}\text{FN}_2\text{O}$ 297.1398; Found 297.1398.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-chlorophenyl)methanone (3s)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (69.4 mg, 74%), mp 144-146 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.77-7.75 (m, 3H), 7.51-7.48 (m, 2H), 7.25-7.22 (m, 1H), 7.07-7.04 (m, 1H), 6.58 (d, J = 7.8 Hz, 1H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.7, 163.2, 141.7, 141.4, 135.2, 132.3, 131.2, 129.8, 123.5, 123.3, 119.9, 112.0, 35.4, 29.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}$ 313.1102; Found 313.1091.

(4-Bromophenyl)(2-(*tert*-butyl)-1*H*-benzo[*d*]imidazol-1-yl)methanone (3t)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (69.7 mg, 65%), mp 153-154 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.77 (d, J = 8.0 Hz, 1H), 7.70-7.65 (m, 4H), 7.26-7.22 (m, 1H), 7.08-7.04 (m, 1H), 6.58 (d, J = 8.0 Hz, 1H), 1.56 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.9, 163.2, 141.4, 135.2, 132.8, 132.3, 131.7,

130.5, 123.5, 123.3, 119.9, 112.0, 35.4, 29.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₈BrN₂O 357.0597; Found 357.0592.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-iodophenyl)methanone (3u)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (57.0 mg, 47%), mp 180-182 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.89 (d, *J* = 8.4 Hz, 2H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 8.4 Hz, 2H), 7.24 (t, *J* = 7.6 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.58 (d, *J* = 8.4 Hz, 1H), 1.55 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 170.2, 163.2, 141.4, 138.8, 135.2, 132.3, 132.0, 123.5, 123.3, 119.9, 112.0, 103.6, 35.4, 29.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₈H₁₈IN₂O 405.0458; Found 405.0451.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(4-(trifluoromethyl)phenyl)methanone (3v)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (70.7 mg, 68%), mp 165-168 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.99 (d, *J* = 8.0 Hz, 2H), 7.85-7.81 (m, 3H), 7.31-7.27 (m, 1H), 7.11-7.07 (m, 1H), 6.53 (d, *J* = 8.0 Hz, 1H), 1.62 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 169.6, 163.3, 141.5, 136.08, 136.05 (q, ²J_{C-F} = 32.9 Hz), 135.0, 131.2, 126.4 (q, ³J_{C-F} = 3.3 Hz), 123.6, 123.5, 123.3 (q, ¹J_{C-F} = 271.2 Hz), 120.0, 112.1, 35.5, 29.7. ¹⁹F NMR (CDCl₃, 565 MHz): δ -63.27 (s). HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₉H₁₈F₃N₂O 347.1366; Found 347.1368.

[1,1'-Biphenyl]-4-yl(2-(*tert*-butyl)-1*H*-benzo[*d*]imidazol-1-yl)methanone (3w)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (59.5 mg, 56%), mp 153-155 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.89 (dt, *J*₁ = 9.0 Hz, *J*₂ = 2.4 Hz, 2H), 7.78 (d, *J* = 8.4 Hz, 1H), 7.73-7.72 (m, 2H), 7.65-7.64 (m, 2H), 7.49-7.47 (m, 2H), 7.44-7.41 (m, 1H), 7.24-7.22 (m, 1H), 7.07-7.04 (m, 1H), 6.68 (d, *J* = 7.8 Hz, 1H), 1.59 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 170.5, 163.2, 147.8, 141.5, 139.2, 135.5, 131.6, 131.4, 129.2, 128.8, 127.9, 127.4, 123.3, 123.1, 119.7, 112.2, 35.5, 29.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₄H₂₃N₂O 355.1805; Found 355.1806.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(*m*-tolyl)methanone (3x)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (69.3 mg, 79%), mp 135-136 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.76 (d, $J = 8.0$ Hz, 1H), 7.68 (s, 1H), 7.55 (d, $J = 7.6$ Hz, 1H), 7.49 (d, $J = 8.0$ Hz, 1H), 7.36 (t, $J = 7.6$ Hz, 1H), 7.22-7.19 (m, 1H), 7.04-7.00 (m, 1H), 6.58 (d, $J = 8.4$ Hz, 1H), 2.40 (s, 3H), 1.57 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.9, 163.3, 141.4, 139.4, 135.8, 135.5, 133.0, 131.2, 129.1, 128.2, 123.2, 123.0, 119.7, 112.2, 35.4, 29.8, 21.3. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ 293.1648; Found 293.1646.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(3-chlorophenyl)methanone (3y)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (62.9 mg, 67%), mp 156-158 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.87 (t, $J = 1.6$ Hz, 1H), 7.77 (d, $J = 8.0$ Hz, 1H), 7.69-7.66 (m, 1H), 7.65-7.62 (m, 1H), 7.45 (t, $J = 8.0$ Hz, 1H), 7.26-7.22 (m, 1H), 7.08-7.04 (m, 1H), 6.56 (d, $J = 8.0$ Hz, 1H), 1.57 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 169.5, 163.3, 141.5, 135.7, 135.1, 134.9, 134.7, 130.58, 130.57, 128.9, 123.5, 123.4, 119.9, 112.1, 35.5, 29.7. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{ClN}_2\text{O}$ 313.1102; Found 313.1100.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(*o*-tolyl)methanone (3z)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (41.2 mg, 47%), mp 123-126 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.73 (d, $J = 8.4$ Hz, 1H), 7.54-7.51 (m, 1H), 7.41 (d, $J = 7.8$ Hz, 1H), 7.37 (dd, $J_1 = 7.8$ Hz, $J_2 = 0.6$ Hz, 1H), 7.24 (t, $J = 7.8$ Hz, 1H), 7.21-7.18 (m, 1H), 6.98-6.95 (m, 1H), 6.27 (d, $J = 8.4$ Hz, 1H), 2.54 (s, 3H), 1.63 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 170.2, 163.5, 141.6, 140.0, 134.8, 133.30, 133.25, 132.2, 130.8, 126.6, 123.5, 123.3, 119.8, 112.3, 35.8, 29.7, 20.4. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}$ 293.1648; Found 293.1646.

(2-Bromophenyl)(2-(*tert*-butyl)-1*H*-benzo[*d*]imidazol-1-yl)methanone (3aa)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (47.1 mg, 44%), mp 138-139 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 7.74-7.71 (m, 2H), 7.57-7.54 (m, 1H), 7.50-7.45 (m, 2H), 7.24-7.19 (m, 1H), 6.99-6.95 (m, 1H), 6.18 (d, $J = 8.4$ Hz, 1H), 1.66 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 167.6, 163.4, 141.8, 136.0, 134.6, 134.3, 133.7, 131.3, 128.2, 123.9, 123.8, 121.4, 120.1, 112.4, 36.0, 29.4. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{18}\text{H}_{18}\text{BrN}_2\text{O}$ 357.0597; Found 357.0606.

Benzo[d][1,3]dioxol-4-yl(2-(*tert*-butyl)-1*H*-benzo[d]imidazol-1-yl)methanone (3bb)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (74.5 mg, 77%), mp 186-188 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.77 (d, $J = 8.4$ Hz, 1H), 7.37 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.8$ Hz, 1H), 7.32 (d, $J = 1.8$ Hz, 1H), 7.24-7.22 (m, 1H), 7.09-7.07 (m, 1H), 6.86 (d, $J = 8.4$ Hz, 1H), 6.74 (d, $J = 8.4$ Hz, 1H), 6.11 (s, 2H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.6, 162.9, 153.7, 148.7, 141.3, 135.6, 128.2, 126.8, 123.2, 123.0, 119.7, 111.9, 110.2, 108.7, 102.5, 35.4, 29.7. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_3$ 323.1390; Found 323.1394.

(2-(*tert*-Butyl)-1*H*-benzo[d]imidazol-1-yl)(naphthalen-1-yl)methanone (3cc)^[4]

Eluent: petroleum ether/ethyl acetate (10:1). White solid (53.2 mg, 54%), mp 171-172 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 8.64 (d, $J = 8.8$ Hz, 1H), 8.15 (d, $J = 8.4$ Hz, 1H), 8.00 (d, $J = 7.6$ Hz, 1H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.70-7.65 (m, 3H), 7.45 (t, $J = 7.6$ Hz, 1H), 7.19-7.15 (m, 1H), 6.89-6.85 (m, 1H), 6.27 (d, $J = 8.0$ Hz, 1H), 1.67 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 169.9, 163.7, 141.5, 135.2, 134.9, 134.2, 131.2, 131.1, 130.3, 128.99, 128.96, 127.2, 125.1, 124.8, 123.4, 123.3, 119.8, 112.6, 35.8, 29.7. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}$ 329.1648; Found 329.1649.

(2-(*tert*-Butyl)-1*H*-benzo[d]imidazol-1-yl)(thiophen-2-yl)methanone (3dd)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (67.4 mg, 79%), mp 147-149 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.86 (dd, $J_1 = 4.8$ Hz, $J_2 = 1.2$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 1H), 7.53 (dd, $J_1 = 3.6$ Hz, $J_2 = 1.2$ Hz, 1H), 7.32 (d, $J = 8.4$ Hz, 1H), 7.24-7.22 (m, 1H), 7.09-7.07 (m, 1H), 6.86 (d, $J = 8.4$ Hz, 1H), 6.74 (d, $J = 8.4$ Hz, 1H), 6.11 (s, 2H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.6, 162.9, 153.7, 148.7, 141.3, 135.6, 128.2, 126.8, 123.2, 123.0, 119.7, 111.9, 110.2, 108.7, 102.5, 35.4, 29.7. HRMS (ESI) m/z: [M+H] $^+$ Calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_3$ 323.1390; Found 323.1394.

Hz, 1H), 7.24 (td, J_1 = 7.8 Hz, J_2 = 1.2 Hz, 1H), 7.15-7.14 (m, 1H), 7.13-7.10 (m, 1H), 6.93 (d, J = 8.4 Hz, 1H), 1.55 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 164.2, 162.4, 141.4, 137.7, 137.4, 137.1, 135.8, 128.9, 123.3, 123.1, 119.7, 111.6, 35.4, 29.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{OS}$ 285.1056; Found 285.1046.

(2-(*tert*-Butyl)-4-methyl-1*H*-benzo[*d*]imidazol-1-yl)(furan-2-yl)methanone (3ee)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (55.9 mg, 66%), mp 68-70 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.71 (dd, J_1 = 1.8 Hz, J_2 = 0.6 Hz, 1H), 7.21 (dd, J_1 = 3.6 Hz, J_2 = 0.6 Hz, 1H), 7.05-7.00 (m, 2H), 6.66 (d, J = 7.8 Hz, 1H), 6.62 (dd, J_1 = 3.6 Hz, J_2 = 1.8 Hz, 1H), 2.67 (s, 3H), 1.53 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 161.4, 159.6, 149.0, 147.6, 140.8, 135.3, 130.0, 123.5, 123.2, 123.1, 113.3, 108.7, 35.4, 29.7, 16.7. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_2$ 283.1441; Found 283.1441.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)ethan-1-one (3ff)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (30.5 mg, 47%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.02 (d, J = 7.8 Hz, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.81-7.78 (m, 1H), 7.54-7.51 (m, 1H), 2.91 (s, 3H), 1.49 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 167.3, 149.8, 132.9, 129.0, 126.3, 124.7, 122.3, 39.4, 29.6, 21.9. HRMS (ESI) m/z: $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{NaO}$ 239.1155; Found 239.1159.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)hexan-1-one (3gg)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (25.3 mg, 31%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.06 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.80-7.77 (m, 1H), 7.53-7.50 (m, 1H), 3.24 (t, J = 7.8 Hz, 2H), 1.94-1.89 (m, 2H), 1.51 (s, 9H), 1.46-1.39 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 170.4, 150.1, 132.6, 129.1, 126.1, 124.3, 121.8, 39.5, 34.2, 31.7, 29.6, 28.0, 22.6, 14.1. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}$ 273.1961; Found 273.1959.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)-3-cyclohexylpropan-1-one (3hh)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (31.9 mg, 34%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.05 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 8.4$ Hz, 1H), 7.79-7.77 (m, 1H), 7.52 (t, $J = 7.8$ Hz, 1H), 3.25 (t, $J = 7.8$ Hz, 2H), 1.85 (d, $J = 13.2$ Hz, 2H), 1.79-1.71 (m, 4H), 1.67-1.65 (m, 1H), 1.49 (s, 9H), 1.38-1.33 (m, 1H), 1.27-1.20 (m, 3H), 1.02-0.96 (m, 2H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 170.8, 150.1, 132.6, 129.1, 126.2, 124.3, 121.7, 39.5, 37.5, 36.0, 33.3, 31.9, 29.6, 26.7, 26.4. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{20}\text{H}_{29}\text{N}_2\text{O}$ 313.2274; Found 313.2270.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)-4-methylpentan-1-one (3ii)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (29.4 mg, 36%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.05 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 8.4$ Hz, 1H), 7.80-7.77 (m, 1H), 7.52 (t, $J = 7.2$ Hz, 1H), 3.25 (t, $J = 7.8$ Hz, 2H), 1.78 (q, $J = 7.8$ Hz, 2H), 1.73-1.69 (m, 1H), 1.49 (s, 9H), 1.00 (d, $J = 6.6$ Hz, 6H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 170.7, 150.1, 132.6, 129.1, 126.2, 124.3, 121.7, 39.5, 37.4, 29.7, 29.6, 28.0, 22.5. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}$ 273.1961; Found 273.1960.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)-3-phenylpropan-1-one (3jj)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (35.8 mg, 39%), mp 44-46 °C. ^1H NMR (CDCl_3 , 400 MHz): δ 8.03 (d, $J = 7.6$ Hz, 1H), 7.98 (d, $J = 8.4$ Hz, 1H), 7.81-7.77 (m, 1H), 7.53-7.49 (m, 1H), 7.31-7.27 (m, 4H), 7.22-7.18 (m, 1H), 3.58 (t, $J = 8.4$ Hz, 2H), 3.28 (t, $J = 8.4$ Hz, 2H), 1.50 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 169.0, 150.1, 141.7, 132.7, 129.2, 128.5, 128.4, 126.3, 126.1, 124.1, 121.8, 39.6, 35.8, 33.7, 29.6. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}$ 307.1805; Found 307.1821.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)-3-(*p*-tolyl)propan-1-one (3kk)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (36.6 mg, 38%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.01 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 8.4$ Hz, 1H), 7.77 (t, $J = 7.8$ Hz, 1H), 7.49 (t, $J = 7.8$ Hz, 1H), 7.17 (d, $J = 7.2$ Hz, 2H), 7.09 (d, $J = 7.8$ Hz, 2H), 3.54 (t, $J = 7.8$ Hz, 2H), 3.22 (t, $J = 8.4$ Hz, 2H), 2.31 (s, 3H), 1.50 (s,

9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.7, 169.2, 150.1, 138.7, 135.5, 132.7, 129.1, 128.4, 126.3, 124.1, 121.8, 39.6, 36.1, 33.3, 29.6, 21.0. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}$ 321.1961; Found 321.1954.

1-(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)-3-(4-chlorophenyl)propan-1-one (3ll)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (40.9 mg, 40%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.00-7.97 (m, 2H), 7.80-7.77 (m, 1H), 7.52-7.50 (m, 1H), 7.23 (d, $J = 8.4$ Hz, 2H), 7.18 (d, $J = 8.4$ Hz, 2H), 3.54 (t, $J = 8.4$ Hz, 2H), 3.25 (t, $J = 7.8$ Hz, 2H), 1.48 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 172.6, 168.6, 150.1, 140.1, 132.8, 131.8, 129.9, 129.2, 128.5, 126.4, 123.9, 121.7, 39.6, 35.5, 32.8, 29.6. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{22}\text{ClN}_2\text{O}$ 341.1415; Found 341.1410.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(cyclohexyl)methanone (3mm)

Eluent: petroleum ether/ethyl acetate (10:1). Colorless liquid (31.6 mg, 37%). ^1H NMR (CDCl_3 , 400 MHz): δ 7.77-7.75 (m, 1H), 7.39-7.36 (m, 1H), 7.32-7.27 (m, 2H), 3.33-3.25 (m, 1H), 2.07 (d, $J = 13.6$ Hz, 2H), 1.91-1.87 (m, 2H), 1.78-1.62 (m, 3H), 1.54 (s, 9H), 1.41-1.30 (m, 3H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 100 MHz): δ 179.1, 162.8, 141.8, 133.7, 123.8, 123.5, 120.3, 111.7, 47.3, 35.8, 29.7, 29.6, 25.55, 25.50. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{25}\text{N}_2\text{O}$ 285.1961; Found 285.1951.

2. Structural elaborations

2.1. Synthesis of 4^[5]

To a reaction tube equipped with a stir bar was charged with **3a** (55.7 mg, 0.2 mmol) and THF (5 mL). The reaction mixture was cooled to 0 °C and added with LiAlH₄ (15.2 mg, 0.4 mmol). The tube was then sealed, and the resulting mixture was allowed to warm to room temperature and stirred for 2 h. Upon completion, it was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine, dried over Na₂SO₄, filtered and concentrated

under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (3:1) as eluent to afford **4**.

2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazole (4**)^[6]**

Eluent: petroleum ether/ethyl acetate (3:1). White solid (30.7 mg, 88%), mp 222-225 °C. ¹H NMR (DMSO-*d*₆, 600 MHz): δ 12.1 (s, 1H), 7.52-7.41 (m, 2H), 7.11-7.10 (m, 2H), 1.40 (s, 9H). ¹³C{¹H} NMR (DMSO, 150 MHz): δ 162.6, 143.3, 135.1, 121.9, 121.2, 118.8, 111.2, 33.6, 29.7. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₁₁H₁₅N₂ 175.1230; Found 175.1230.

2.2. Synthesis of **5^[7]**

To a reaction tube equipped with a stir bar were charged with **3aa** (35.7 mg, 0.1 mmol), DMSO (1 mL), Pd(OAc)₂ (1.1 mg, 0.005 mmol), PPh₃ (5.2 mg, 0.02 mmol), K₃PO₄ (25.5 mg, 0.12 mmol) and ethynylbenzene (16.5 μL, 0.15 mmol). The tube was then sealed, and the resulting mixture was stirred at 80 °C for 24 h under argon atmosphere. Upon completion, it was diluted with ethyl acetate (20 mL) and washed with water and brine. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (20:1) as the eluent to give **5**.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(2-(phenylethynyl)phenyl)methanone (5**)**

Eluent: petroleum ether/ethyl acetate (20:1). White solid (32.9 mg, 87%), mp 191-193 °C. ¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, *J* = 7.6 Hz, 1H), 7.78 (d, *J* = 8.0 Hz, 1H), 7.69-7.66 (m, 2H), 7.61-7.56 (m, 1H), 7.33-7.30 (m, 3H), 7.26-7.22 (m, 3H), 7.05-7.01 (m, 1H), 6.42 (d, *J* = 8.4 Hz, 1H), 1.64 (s, 9H). ¹³C{¹H} NMR (CDCl₃, 100 MHz): δ 169.0, 163.0, 141.8, 135.6, 134.9, 134.3, 133.0, 131.9, 130.8, 128.92, 128.89, 128.3, 123.7, 123.54, 123.47, 121.9, 119.8, 112.1, 95.2, 85.6, 35.7, 29.6. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₆H₂₃N₂O 379.1805; Found 379.1800.

2.3. Synthesis of **6**^[8]

To a reaction tube equipped with a stir bar were charged with **3aa** (71.5 mg, 0.2 mmol), piperidine (1 mL), Pd(PPh₃)₄ (4.6 mg, 0.004 mmol) and CuI (3.8 mg, 0.02 mmol). The tube was then sealed, and the resulting mixture was stirred at room temperature for 15 h. Upon completion, it was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **6**.

(2-(*tert*-Butyl)-1*H*-benzo[*d*]imidazol-1-yl)(2-(piperidin-1-yl)phenyl)methanone (**6**)

Eluent: petroleum ether/ethyl acetate (10:1). White solid (23.2 mg, 32%), mp 194-196 °C. ¹H NMR (CDCl₃, 600 MHz): δ 7.72 (d, *J* = 7.8 Hz, 1H), 7.52 (t, *J* = 7.2 Hz, 1H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.18 (t, *J* = 7.8 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 1H), 7.02 (t, *J* = 7.8 Hz, 1H), 6.93 (t, *J* = 7.8 Hz, 1H), 6.32 (d, *J* = 9.0 Hz, 1H), 2.97 (br s, 2H), 2.79 (br s, 2H), 1.65 (s, 9H), 1.41-1.37 (m, 2H), 1.30-1.26 (m, 4H). ¹³C{¹H} NMR (CDCl₃, 150 MHz): δ 168.6, 163.6, 153.7, 141.7, 135.0, 134.1, 132.3, 126.6, 123.3, 123.2, 121.6, 119.9, 119.7, 113.0, 53.8, 36.3, 29.3, 25.9, 23.8. HRMS (ESI) m/z: [M+H]⁺ Calcd for C₂₃H₂₇N₃NaO 384.2046; Found 384.2068.

2.4. Synthesis of **7**^[9]

To a reaction tube equipped with a stir bar were charged with **3aa** (35.7 mg, 0.1 mmol), dioxane (1 mL), Pd(OAc)₂ (2.2 mg, 0.01 mmol), PPh₃ (15.7 mg, 0.06 mmol), K₂CO₃ (55.3 mg, 0.4 mmol) and phenylboronic acid (13.4 mg, 0.11 mmol). The tube was then sealed, and the resulting mixture was stirred at 80 °C for 24 h under argon atmosphere. Upon completion, it was diluted with ethyl acetate (20 mL) and washed with water and brine. The organic layer was dried over anhydrous Na₂SO₄, filetered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel with petroleum ether/ethyl acetate (40:1) as the eluent to give **7**.

[1,1'-Biphenyl]-2-yl(2-(*tert*-butyl)-1*H*-benzo[*d*]imidazol-1-yl)methanone (**7**)

Eluent: petroleum ether/ethyl acetate (40:1). White solid (32.6 mg, 92%), mp 209-211 °C. ^1H NMR (CDCl_3 , 600 MHz): δ 7.69-7.65 (m, 2H), 7.57 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.8$ Hz, 1H), 7.50-7.45 (m, 2H), 7.26-7.16 (m, 6H), 7.00-6.98 (m, 1H), 6.30 (d, $J = 8.4$ Hz, 1H), 1.54 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 169.1, 163.8, 142.9, 141.7, 139.1, 134.5, 134.0, 132.6, 131.7, 130.0, 128.5, 128.3, 128.0, 127.8, 123.6, 123.5, 119.9, 113.3, 36.2, 29.3. HRMS (ESI) m/z: $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{24}\text{H}_{23}\text{N}_2\text{O}$ 355.1805; Found 355.1804.


3. Gram-scale synthesis of **3a**

To a reaction tube equipped with a stir bar were charged with *N*-phenylpivalimidamide (**1a**, 1.058 g, 6 mmol), ethyl acetate (25 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (77.3 mg, 0.125 mmol), AgSbF_6 (171.8 mg, 0.5 mmol), $\text{Zn}(\text{OAc})_2$ (275.2 mg, 1.5 mmol) and 3-phenyl-1,4,2-dioxazol-5-one (**2a**, 0.816 g, 5 mmol). The tube was then sealed, and the resulting mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water and extracted with ethyl acetate (30 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (0.849 g, 61%).

III. Mechanism studies


1. Mechanism studies (I)

To a reaction tube equipped with a stir bar were charged with **1a** (52.9 mg, 0.3 mmol), ethyl acetate (1.5 mL), CD₃OD (0.12 mL, 3 mmol), [RhCp^{*}Cl₂]₂ (4.6 mg, 0.0075 mmol), AgSbF₆ (10.3 mg, 0.03 mmol), and Zn(OAc)₂ (16.5 mg, 0.09 mmol). The resulting mixture was stirred at 110 °C under air for 30 min. Afterwards, it was cooled to room temperature, quenched with water and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (5:1) as eluent to give a mixture of **1a** and **1a-d_n**. Upon analyzing the ¹H NMR spectrum of the mixture, the deuteration ratio was determined to be 20%.




1.2. H/D exchange experiment (II)

To a reaction tube equipped with a stir bar were charged with **1a** (42.3 mg, 0.24 mmol), **2a** (32.6 mg, 0.2 mmol), ethyl acetate (1 mL), CD₃OD (81 μ L, 2 mmol), [RhCp^{*}Cl₂]₂ (3.1 mg, 0.005 mmol), AgSbF₆ (6.9 mg, 0.02 mmol), and Zn(OAc)₂ (11.0 mg, 0.06 mmol). The resulting mixture was stirred at 110 °C under air for 3 h. Afterwards, it was cooled to room temperature, quenched with water and extracted with ethyl acetate (10 mL \times 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to give a mixture of **3a** and **3a-d_n**. Upon analyzing the ¹H NMR spectrum of the mixture, the deuteration ratio was determined to be 54%.




1.3. Kinetic isotope effect study

To a reaction tube equipped with a stir bar were added **1a** (105.6 mg, 0.6 mmol), **1a-d₅** (108.6 mg, 0.6 mmol), ethyl acetate (2.5 mL), **2a** (97.8 mg, 0.6 mmol), [RhCp*Cl₂]₂ (7.7 mg, 0.0125 mmol), AgSbF₆ (17.2 mg, 0.05 mmol) and Zn(OAc)₂ (27.5 mg, 0.15 mmol) with stirring. After the tube was sealed, the mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford a mixture of **3a** and **3a-d₄**. Upon analyzing the ¹H NMR spectrum of the mixture, the ratio of **3a** to **3a-d₄** was determined to be 0.6:0.4. Accordingly, the intermolecular KIE (*k_H/k_D*) was calculated to be 1.5.



1.4. Competition study of substrates with different electronic characteristics

To a reaction tube equipped with a stir bar were added **1b** (57.1 mg, 0.3 mmol), **1e** (58.3 mg, 0.3 mmol), ethyl acetate (1.5 mL), **2a** (48.9 mg, 0.3 mmol), $[\text{RhCp}^*\text{Cl}_2]_2$ (4.6 mg, 0.0075 mmol), AgSbF_6 (10.3 mg, 0.03 mmol) and Zn(OAc)_2 (16.5 mg, 0.09 mmol) with stirring. After the tube was sealed, the mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford a mixture of **3b** and **3e**. Upon analyzing the ^1H NMR spectrum of the mixture, the ratio of **3b** to **3e** was determined to be 0.7:1.



2. Mechanism studies (II)

2.1. To a reaction tube equipped with a stir bar were charged with *N*-phenylpivalimidamide (**1a**, 63.5 mg, 0.36 mmol), ethyl acetate (1.5 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (4.6 mg, 0.0075 mmol), AgSbF_6 (10.3 mg, 0.03 mmol),

Zn(OAc)_2 (16.5 mg, 0.09 mmol) and 3-phenyl-1,4,2-dioxazol-5-one (**2a**, 48.9 mg, 0.3 mmol). The tube was sealed, and the reaction mixture was stirred at room temperature under air for 10 h. Upon completion, it was quenched with water (10 mL) and extracted with ethyl acetate (10 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using dichloromethane/methanol (10:1) as eluent to afford **IV** (73.7 mg, 83%).

N-(2-Pivalimidodiphenyl)benzamide (IV)

Eluent: dichloromethane/methanol (10:1). White solid (73.7 mg, 83%), mp 163-164 °C. ^1H NMR (DMSO, 600 MHz): δ 9.20 (br s, 1H), 8.21 (d, J = 4.2 Hz, 1H), 7.86 (d, J = 7.2 Hz, 2H), 7.60 (t, J = 7.2 Hz, 1H), 7.55 (t J = 7.8 Hz, 2H), 7.09-6.94 (m, 3H), 6.22-6.16 (m, 2H), 1.26 (s, 9H). $^{13}\text{C}\{\text{H}\}$ NMR (CDCl_3 , 150 MHz): δ 166.8, 164.9, 137.9, 135.3, 131.6, 131.5, 128.7, 127.0, 124.2, 123.9, 120.5, 120.2, 37.3, 28.6. HRMS (ESI) m/z: [M+H]⁺ Calcd for $\text{C}_{18}\text{H}_{22}\text{N}_3\text{O}$ 296.1757; Found 296.1766.

2.2. To a reaction tube equipped with a stir bar were charged with **IV** (88.6 mg, 0.3 mmol), ethyl acetate (1.5 mL), $[\text{RhCp}^*\text{Cl}_2]_2$ (4.6 mg, 0.0075 mmol), AgSbF_6 (10.3 mg, 0.03 mmol) and Zn(OAc)_2 (16.5 mg, 0.09 mmol). The tube was sealed, and the reaction mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10 mL) and extracted with ethyl acetate (10 mL \times 3). The combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (78.5 mg, 94%).

2.3. To a reaction tube equipped with a stir bar were charged with **IV** (88.6 mg, 0.3 mmol), ethyl acetate (1.5 mL) and $[\text{RhCp}^*\text{Cl}_2]_2$ (4.6 mg, 0.0075 mmol). The tube was sealed, and the reaction mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10


mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (23.4 mg, 28%).


2.4. To a reaction tube equipped with a stir bar were charged with **IV** (88.6 mg, 0.3 mmol), ethyl acetate (1.5 mL) and AgSbF₆ (10.3 mg, 0.03 mmol). The tube was sealed, and the reaction mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (73.5 mg, 88%).


2.5. To a reaction tube equipped with a stir bar were charged with **IV** (88.6 mg, 0.3 mmol), ethyl acetate (1.5 mL) and Zn(OAc)₂ (16.5 mg, 0.09 mmol). The tube was sealed, and the reaction mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (71.0 mg, 85%).



2.6. To a reaction tube equipped with a stir bar were charged with **IV** (88.6 mg, 0.3 mmol) and ethyl acetate (1.5 mL). The tube was sealed, and the reaction mixture was stirred at 110 °C under air for 10 h. Upon completion, it was cooled to room temperature, quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether/ethyl acetate (10:1) as eluent to afford **3a** (21.7 mg, 26%).

IV. Copies of NMR spectra of products 3a-3mm













(CDCl₃, 600 MHz)





3d
(CDCl₃, 150 MHz)




3e
 $(\text{CDCl}_3, 100 \text{ MHz})$











3e


(CDCl₃, 565 MHz)





























































3r
(CDCl₃, 565 MHz)


















— 63.272 —












(CDCl₃, 150 MHz)








(CDCl₃, 100 MHz)












32























3ff
(CDCl₃, 150 MHz)







8.054
8.040
7.976
7.962
7.793
7.791
7.779
7.766
7.766
7.527
7.515
7.502
7.259

3.265
3.252
3.239

1.861
1.839
1.786
1.774
1.760
1.748
1.739
1.733
1.729
1.718
1.712
1.670
1.651
1.489
1.382
1.375
1.364
1.358
1.352
1.345
1.265
1.254
1.244
1.239
1.223
1.218
1.198
1.185
1.180
1.175
1.159
1.139
1.022
1.017
1.017
0.997
0.982
0.978
0.962



3hh
(CDCl₃, 600 MHz)




172.657
170.841

150.133


132.611
129.147
126.150
124.327
121.709



77.244
77.026
76.821



39.465
37.496
35.987
33.282
31.874
29.577
26.675
26.384








3hh
(CDCl₃, 150 MHz)



















3mm
(CDCl_3 , 400 MHz)








3mm
(CDCl_3 , 150 MHz)





V Copies of NMR spectra of products 4-7









(CDCl₃, 600 MHz)




6
(CDCl₃, 150 MHz)





VI. Copies of NMR spectra of intermediate IV



VII. X-ray crystal structure and data of product **3o**




Fig. S1 X-ray crystal structure of **3o** with 50% ellipsoid probability

X-ray structure determination. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a petroleum ether/ethyl acetate (8:1) solution of **3o**. Crystal data collection and refinement parameters of **3o** are summarized in Table S1. Intensity data were collected at 293 K on a SuperNova Dual diffractometer using mirror-monochromated Cu K α radiation, $\lambda = 1.54184 \text{ \AA}$. The data were corrected for decay, Lorentz, and polarization effects as well as absorption and beam corrections based on the multi-scan technique. Using Olex2, the structure was solved with the SHELXS structure solution program using Direct Methods and refined with the SHELXL refinement package using Least Squares minimisation. Nonhydrogen atoms were refined with anisotropic displacement parameters. The H-atoms were either located or calculated and subsequently treated with a riding model.

Table S1 Crystallographic data and structure refinement results of **3o**

Empirical formula	C ₁₉ H ₂₀ N ₂ O
Formula weight	292.37
Temp, K	293 (2)
Crystal system	monoclinic
Space group	P2 ₁ /n
<i>a</i> , Å	9.7662(2)
<i>b</i> , Å	9.2325(2)
<i>c</i> , Å	18.7919(4)
α (°)	90

β (°)	101.473(2)
γ (°)	90
Volume, Å ³	1660.54(6)
Z	4
ρ_{calc} , g cm ⁻³	1.169
λ , Å	1.54184
μ , mm ⁻¹	0.571
No. of data collected	6499
No. of unique data	3143
R_{int}	0.0189
Goodness-of-fit on F^2	1.070
R_1 , wR ₂ ($I > 2\sigma(I)$)	0.0542, 0.1354
R_1 , wR ₂ (all data)	0.0666, 0.1442

VIII. References

- [1] G. Brasche and S. L. Buchwald, C–H Functionalization/C–N Bond Formation: Copper-Catalyzed Synthesis of Benzimidazoles from Amidines, *Angew. Chem. Int. Ed.*, 2008, **47**, 1932–1934.
- [2] K. M. van Vliet, L. H. Polak, M. A. Siegler, J. I. van der Vlugt, C. F. Guerra and B. Bruin, Efficient Copper Catalyzed Multicomponent Synthesis of *N*-Acyl Amidines via Acyl Nitrenes, *J. Am. Chem. Soc.*, 2019, **141**, 15240–15249.
- [3] K.-I. Fujita, Y. Takahashi, M. Owaki, K. Yamamoto and R. Yamaguchi, Synthesis of Five-, Six-, and Seven-Membered Ring Lactams by Cp^{*}Rh Complex-Catalyzed Oxidative *N*-Heterocyclization of Amino Alcohols, *Org. Lett.*, 2004, **6**, 2785–2788.
- [4] J. Romero-Parra, J. Mella-Raipan, V. Palmieri, M. Allara, M. J. Torres, H. Pessoa-Mahana, P. Iriaga-Vasquez, R. Escobar, M. Faúndez, V. Di Marzo and C. D. Pessoa-Mahana, Synthesis, Binding Assays, Cytotoxic Activity and Docking Studies of Benzimidazole and Benzothiophene Derivatives with Selective Affinity for the CB2 Cannabinoid Receptor, *Eur. J. Med. Chem.*, 2016, **124**, 17–35.
- [5] Z.-J. Zhang, Y.-H. Wen, J. Song and L.-Z. Gong, Kinetic Resolution of Aziridines Enabled by *N*-Heterocyclic Carbene/Copper Cooperative Catalysis: Carbene Dose-Controlled Chemo-Switchability, *Angew. Chem. Int. Ed.*, 2021, **60**, 3268–3276.
- [6] J. Huang, Y. He, Y. Wang and Q. Zhu, Synthesis of Benzimidazoles by PIDA-Promoted Direct C(sp²)–H Imidation of *N*-Arylamidines, *Chem. Eur. J.*, 2012, **18**, 13964–13967.
- [7] X. Song, Q. Zhou, J. Zhao, Y. Jiang, X. Zhang, X. Zhang and X. Fan, Synthesis of 1,3-Benzodiazepines through [5 + 2] Annulation of *N*-Aryl Amidines with Propargylic Esters, *Org. Lett.*, 2020, **22**, 9506–9512.
- [8] D. J. Burns and H. W. Lam, Catalytic 1,4-Rhodium(III) Migration Enables 1,3-Enynes to Function as One-Carbon Oxidative Annulation Partners in C–H Functionalizations, *Angew. Chem. Int. Ed.*, 2014, **126**, 10089–10093.

- [9] X. Song, C. Gao, X. Zhang and X. Fan, Synthesis of Diversely Functionalized 2*H*-Chromenes through Pd-Catalyzed Cascade Reactions of 1,1-Dibromoolefin Derivatives with Arylboronic Acids, *J. Org. Chem.*, 2018, **83**, 15256–15267.